These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 32876903)

  • 61. Baricitinib inhibits structural joint damage progression in patients with rheumatoid arthritis-a comprehensive review.
    Emery P; Durez P; Hueber AJ; de la Torre I; Larsson E; Holzkämper T; Tanaka Y
    Arthritis Res Ther; 2021 Jan; 23(1):3. PubMed ID: 33397481
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Everolimus in patients with rheumatoid arthritis receiving concomitant methotrexate: a 3-month, double-blind, randomised, placebo-controlled, parallel-group, proof-of-concept study.
    Bruyn GA; Tate G; Caeiro F; Maldonado-Cocco J; Westhovens R; Tannenbaum H; Bell M; Forre O; Bjorneboe O; Tak PP; Abeywickrama KH; Bernhardt P; van Riel PL;
    Ann Rheum Dis; 2008 Aug; 67(8):1090-5. PubMed ID: 18037627
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a forty-eight-week randomized, double-blind, placebo-controlled, parallel-group phase III trial.
    Rigby W; Tony HP; Oelke K; Combe B; Laster A; von Muhlen CA; Fisheleva E; Martin C; Travers H; Dummer W
    Arthritis Rheum; 2012 Feb; 64(2):350-9. PubMed ID: 21905001
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial.
    Kremer JM; Dougados M; Emery P; Durez P; Sibilia J; Shergy W; Steinfeld S; Tindall E; Becker JC; Li T; Nuamah IF; Aranda R; Moreland LW
    Arthritis Rheum; 2005 Aug; 52(8):2263-71. PubMed ID: 16052582
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of etanercept in patients with moderately active rheumatoid arthritis despite DMARD therapy.
    Hobbs K; Deodhar A; Wang B; Bitman B; Nussbaum J; Chung J; Collier DH
    Springerplus; 2015; 4():113. PubMed ID: 25793152
    [TBL] [Abstract][Full Text] [Related]  

  • 66. A randomized, double-blind, placebo-controlled, twelve-week, dose-ranging study of decernotinib, an oral selective JAK-3 inhibitor, as monotherapy in patients with active rheumatoid arthritis.
    Fleischmann RM; Damjanov NS; Kivitz AJ; Legedza A; Hoock T; Kinnman N
    Arthritis Rheumatol; 2015 Feb; 67(2):334-43. PubMed ID: 25385260
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs.
    Fleischmann R; Cutolo M; Genovese MC; Lee EB; Kanik KS; Sadis S; Connell CA; Gruben D; Krishnaswami S; Wallenstein G; Wilkinson BE; Zwillich SH
    Arthritis Rheum; 2012 Mar; 64(3):617-29. PubMed ID: 21952978
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Cost-effectiveness analysis of baricitinib versus adalimumab for the treatment of moderate-to-severe rheumatoid arthritis in Spain.
    Schlueter M; Finn E; Díaz S; Dilla T; Inciarte-Mundo J; Fakhouri W
    Clinicoecon Outcomes Res; 2019; 11():395-403. PubMed ID: 31239736
    [No Abstract]   [Full Text] [Related]  

  • 69. Maintenance of Clinical and Radiographic Benefit With Intravenous Golimumab Therapy in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy: Week-112 Efficacy and Safety Results of the Open-Label Long-Term Extension of a Phase III, Double-Blind, Randomized, Placebo-Controlled Trial.
    Bingham CO; Mendelsohn AM; Kim L; Xu Z; Leu J; Han C; Lo KH; Westhovens R; Weinblatt ME;
    Arthritis Care Res (Hoboken); 2015 Dec; 67(12):1627-36. PubMed ID: 25623393
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Response to baricitinib based on prior biologic use in patients with refractory rheumatoid arthritis.
    Genovese MC; Kremer JM; Kartman CE; Schlichting DE; Xie L; Carmack T; Pantojas C; Sanchez Burson J; Tony HP; Macias WL; Rooney TP; Smolen JS
    Rheumatology (Oxford); 2018 May; 57(5):900-908. PubMed ID: 29415145
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Clinical outcomes in patients switched from adalimumab to baricitinib due to non-response and/or study design: phase III data in patients with rheumatoid arthritis.
    Tanaka Y; Fautrel B; Keystone EC; Ortmann RA; Xie L; Zhu B; Issa M; Patel H; Gaich CL; de Bono S; Rooney TP; Taylor PC
    Ann Rheum Dis; 2019 Jul; 78(7):890-898. PubMed ID: 31040122
    [TBL] [Abstract][Full Text] [Related]  

  • 72. A phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from the PLANETRA study.
    Yoo DH; Racewicz A; Brzezicki J; Yatsyshyn R; Arteaga ET; Baranauskaite A; Abud-Mendoza C; Navarra S; Kadinov V; Sariego IG; Hong SS; Lee SY; Park W
    Arthritis Res Ther; 2016 Apr; 18():82. PubMed ID: 27038608
    [TBL] [Abstract][Full Text] [Related]  

  • 73. [Efficacy of Shenshi Qianghuo Dihuang Decoction in rheumatoid arthritis: a randomized controlled trial].
    Chen ZW; Sun J; Li YM; Chen YQ
    Zhong Xi Yi Jie He Xue Bao; 2010 Jan; 8(1):35-9. PubMed ID: 20082756
    [TBL] [Abstract][Full Text] [Related]  

  • 74. A study to evaluate the safety, tolerability, and efficacy of brodalumab in subjects with rheumatoid arthritis and an inadequate response to methotrexate.
    Pavelka K; Chon Y; Newmark R; Lin SL; Baumgartner S; Erondu N
    J Rheumatol; 2015 Jun; 42(6):912-9. PubMed ID: 25877498
    [TBL] [Abstract][Full Text] [Related]  

  • 75. VX-509 (Decernotinib), an Oral Selective JAK-3 Inhibitor, in Combination With Methotrexate in Patients With Rheumatoid Arthritis.
    Genovese MC; van Vollenhoven RF; Pacheco-Tena C; Zhang Y; Kinnman N
    Arthritis Rheumatol; 2016 Jan; 68(1):46-55. PubMed ID: 26473751
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Comparative efficacy and safety of baricitinib 2 mg and 4 mg in patients with active rheumatoid arthritis : A Bayesian network meta-analysis of randomized controlled trials.
    Lee YH; Bae SC
    Z Rheumatol; 2018 May; 77(4):335-342. PubMed ID: 28097393
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Infections in baricitinib clinical trials for patients with active rheumatoid arthritis.
    Winthrop KL; Harigai M; Genovese MC; Lindsey S; Takeuchi T; Fleischmann R; Bradley JD; Byers NL; Hyslop DL; Issa M; Nishikawa A; Rooney TP; Witt S; Dickson CL; Smolen JS; Dougados M
    Ann Rheum Dis; 2020 Oct; 79(10):1290-1297. PubMed ID: 32788396
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Comparative efficacy and safety of tofacitinib, baricitinib, upadacitinib, filgotinib and peficitinib as monotherapy for active rheumatoid arthritis.
    Ho Lee Y; Gyu Song G
    J Clin Pharm Ther; 2020 Aug; 45(4):674-681. PubMed ID: 32495356
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial.
    Wallace DJ; Furie RA; Tanaka Y; Kalunian KC; Mosca M; Petri MA; Dörner T; Cardiel MH; Bruce IN; Gomez E; Carmack T; DeLozier AM; Janes JM; Linnik MD; de Bono S; Silk ME; Hoffman RW
    Lancet; 2018 Jul; 392(10143):222-231. PubMed ID: 30043749
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Efficacy and Safety of Subcutaneous and Intravenous Loading Dose Regimens of Secukinumab in Patients with Active Rheumatoid Arthritis: Results from a Randomized Phase II Study.
    Tlustochowicz W; Rahman P; Seriolo B; Krammer G; Porter B; Widmer A; Richards HB
    J Rheumatol; 2016 Mar; 43(3):495-503. PubMed ID: 26834211
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.